DK3500593T3 - Ukendte t-cellereceptorer og immunterapi under anvendelse deraf - Google Patents

Ukendte t-cellereceptorer og immunterapi under anvendelse deraf Download PDF

Info

Publication number: DK3500593T3
Authority: DK; Denmark
Prior art keywords: immuntery; unknown; therapy; cell receptors; receptors
Prior art date: 2016-08-17

Application number

DK17739220.6T

Other languages

English (en)

Inventor

Leonie Alten

Dominik Maurer

Steffen Walter

Sebastian Bunk

Original Assignee

Immatics Biotechnologies Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-08-17

Filing date

2017-07-04

Publication date

2021-11-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60419980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3500593(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-07-04 Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh

2021-11-01 Application granted granted Critical

2021-11-01 Publication of DK3500593T3 publication Critical patent/DK3500593T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4269—NY-ESO
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Hematology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)

DK17739220.6T 2016-08-17 2017-07-04 Ukendte t-cellereceptorer og immunterapi under anvendelse deraf DK3500593T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201662376059P	2016-08-17	2016-08-17
DE102016115246.3A DE102016115246C5 (de)	2016-08-17	2016-08-17	Neue t-zellrezeptoren und deren verwendung in immuntherapie
US201662376632P	2016-08-18	2016-08-18
PCT/EP2017/066630 WO2018033291A1 (en)	2016-08-17	2017-07-04	T cell receptors and immune therapy using the same

Publications (1)

Publication Number	Publication Date
DK3500593T3 true DK3500593T3 (da)	2021-11-01

Family

ID=60419980

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK17739220.6T DK3500593T3 (da)	2016-08-17	2017-07-04	Ukendte t-cellereceptorer og immunterapi under anvendelse deraf

Country Status (18)

Country	Link
US (2)	US10550182B2 (da)
EP (1)	EP3500593B1 (da)
JP (2)	JP6964351B2 (da)
CN (1)	CN109563149A (da)
AU (2)	AU2017312361B2 (da)
BR (1)	BR112019001922A2 (da)
CA (1)	CA3031995A1 (da)
CR (1)	CR20190095A (da)
DE (1)	DE102016115246C5 (da)
DK (1)	DK3500593T3 (da)
LT (1)	LT3500593T (da)
MA (1)	MA45976B1 (da)
MX (1)	MX395287B (da)
PE (1)	PE20190477A1 (da)
RS (1)	RS62498B1 (da)
SG (1)	SG11201900955VA (da)
TW (1)	TWI775768B (da)
WO (1)	WO2018033291A1 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201423361D0 (en) *	2014-12-30	2015-02-11	Immatics Biotechnologies Gmbh	Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
ZA201900664B (en) *	2016-08-17	2021-09-29	Paul Ehrlich Strasse 15 Tuebingen 72076 Germany	T cell receptors and immune therapy using the same
EA201992131A1 (ru) *	2017-03-15	2020-02-06	Фред Хатчинсон Кэнсер Рисерч Сентер	Высокоаффинные специфичные к mage-a1 tcr и их применение
KR102794702B1 (ko)	2017-09-01	2025-04-11	다나-파버 캔서 인스티튜트 인크.	암의 치료를 위한 bcma 및 taci 항원에 특이적인 면역원성 펩타이드
DE102017125888A1 (de)	2017-11-06	2019-05-23	Immatics Biotechnologies Gmbh	Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie
US10618956B2 (en)	2017-11-06	2020-04-14	Immatics Biotechnologies Gmbh	Engineered T cell receptors and immune therapy using the same
US11464800B2 (en)	2018-02-09	2022-10-11	Immatics US, Inc.	Methods for manufacturing T cells
DE102018108612A1 (de)	2018-03-21	2019-09-26	Immatics US, Inc.	Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
CN112292037B (zh)	2018-06-19	2024-03-22	帝斯曼知识产权资产管理有限公司	脂解酶变体
CN120607607A (zh) *	2019-01-22	2025-09-09	美国卫生和人力服务部	针对含有g12r突变的ras的hla第ii类限制性t细胞受体
CA3131138A1 (en)	2019-03-06	2020-09-10	Dana-Farber Cancer Institute, Inc.	T cell receptors specific to b-cell maturation antigen for treatment of cancer
DE102019108125B4 (de)	2019-03-28	2022-02-03	Immatics US, Inc.	Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
US20200297768A1 (en)	2019-03-19	2020-09-24	Immatics US, Inc.	Cd28 t cell cultures, compositions, and methods of using thereof
MA56036A (fr)	2019-05-27	2022-04-06	Immatics Us Inc	Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive
CN114303060A (zh)	2019-06-06	2022-04-08	伊玛提克斯生物技术有限公司	使用序列相似肽进行反向选择分选
US20210032370A1 (en)	2019-08-02	2021-02-04	Immatics Biotechnologies Gmbh	Recruiting agent further binding an mhc molecule
JP2023515131A (ja)	2020-02-24	2023-04-12	イマティクスユーエス，アイエヌシー．	がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法
DE102020106710A1 (de)	2020-03-11	2021-09-16	Immatics US, Inc.	Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020111571A1 (de)	2020-03-11	2021-09-16	Immatics US, Inc.	Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
CA3186594A1 (en) *	2020-06-09	2021-12-16	Board Of Regents, The University Of Texas System	Engineered t cell receptors and methods of use
WO2022040631A1 (en)	2020-08-21	2022-02-24	Immatics US, Inc.	Methods for isolating cd8+ selected t cells
WO2022147029A2 (en)	2020-12-31	2022-07-07	Immatics US, Inc.	Cd8 polypeptides, compositions, and methods of using thereof
DE102021100038A1 (de)	2020-12-31	2022-06-30	Immatics US, Inc.	Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
TW202309090A (zh)	2021-05-05	2023-03-01	德商英麥提克生物技術股份有限公司	經改善之ｂｍａ０３１抗原結合性多肽
EP4392441A1 (en)	2021-08-24	2024-07-03	Immatics US, Inc.	Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange
WO2023044488A1 (en)	2021-09-20	2023-03-23	Immatics US, Inc.	Monocyte depletion of t cells populations for t-cell therapy
US20230192886A1 (en)	2021-11-08	2023-06-22	Immatics Biotechnologies Gmbh	Adoptive cell therapy combination treatment and compositions thereof
WO2023081461A1 (en)	2021-11-08	2023-05-11	Immatics US, Inc.	Methods for generating cell spheroids
JP2025515604A (ja)	2022-04-28	2025-05-20	イマティクスユーエス，アイエヌシー．	ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法
WO2023212697A1 (en)	2022-04-28	2023-11-02	Immatics US, Inc.	Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
EP4514821A1 (en)	2022-04-28	2025-03-05	Immatics US, Inc.	Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
EP4519418A1 (en)	2022-05-05	2025-03-12	Immatics US, Inc.	Methods for improving t cell efficacy
CN117986350B (zh) *	2023-02-23	2024-08-16	暨南大学	一种识别mage-a3抗原短肽的t细胞受体及其应用
US20250134931A1 (en)	2023-11-01	2025-05-01	Immatics US, Inc.	Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
CN120718134A (zh) *	2025-08-25	2025-09-30	北京立康生命科技有限公司	靶向col6a3肽的t细胞受体及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2089661C (en)	1990-08-29	2007-04-03	Nils Lonberg	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5714352A (en)	1996-03-20	1998-02-03	Xenotech Incorporated	Directed switch-mediated DNA recombination
EP1257289A1 (en)	2000-02-08	2002-11-20	The Penn State Research Foundation	Immunotherapy using interleukin 13 receptor subunit alpha 2
US7820401B2 (en) *	2004-08-23	2010-10-26	Albert Einstein College Of Medicine Of Yeshiva University	Collagen VI and cancer
EP1762575A1 (en) *	2005-09-12	2007-03-14	Ganymed Pharmaceuticals AG	Identification of tumor-associated antigens for diagnosis and therapy
US8105831B2 (en) *	2007-03-09	2012-01-31	University Of Washington	Parvoviral production of HLA homozygous cells
GB0911566D0 (en)	2009-07-03	2009-08-12	Immunocore Ltd	T cell receptors
US9228007B1 (en) *	2010-03-11	2016-01-05	The Regents Of The University Of California	Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells
GB201004551D0 (en) *	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
CN105452288B (zh) *	2013-07-15	2019-08-13	美国卫生和人力服务部	抗人乳头瘤病毒16 e6 t细胞受体
US10738278B2 (en) *	2014-07-15	2020-08-11	Juno Therapeutics, Inc.	Engineered cells for adoptive cell therapy
EP3753948A1 (en) *	2014-11-05	2020-12-23	Genentech, Inc.	Methods of producing two chain proteins in bacteria

2016
- 2016-08-17 DE DE102016115246.3A patent/DE102016115246C5/de not_active Expired - Fee Related
2017
- 2017-07-04 SG SG11201900955VA patent/SG11201900955VA/en unknown
- 2017-07-04 EP EP17739220.6A patent/EP3500593B1/en active Active
- 2017-07-04 MX MX2019001769A patent/MX395287B/es unknown
- 2017-07-04 BR BR112019001922A patent/BR112019001922A2/pt not_active IP Right Cessation
- 2017-07-04 MA MA45976A patent/MA45976B1/fr unknown
- 2017-07-04 WO PCT/EP2017/066630 patent/WO2018033291A1/en not_active Ceased
- 2017-07-04 DK DK17739220.6T patent/DK3500593T3/da active
- 2017-07-04 CA CA3031995A patent/CA3031995A1/en active Pending
- 2017-07-04 CN CN201780049787.2A patent/CN109563149A/zh active Pending
- 2017-07-04 AU AU2017312361A patent/AU2017312361B2/en not_active Ceased
- 2017-07-04 PE PE2019000285A patent/PE20190477A1/es unknown
- 2017-07-04 JP JP2019508259A patent/JP6964351B2/ja active Active
- 2017-07-04 CR CR20190095A patent/CR20190095A/es unknown
- 2017-07-04 RS RS20211327A patent/RS62498B1/sr unknown
- 2017-07-04 LT LTEPPCT/EP2017/066630T patent/LT3500593T/lt unknown
- 2017-08-11 TW TW106127257A patent/TWI775768B/zh not_active IP Right Cessation
- 2017-08-15 US US15/677,651 patent/US10550182B2/en not_active Expired - Fee Related
2018
- 2018-07-13 US US16/035,300 patent/US10526407B2/en active Active
2021
- 2021-03-10 AU AU2021201518A patent/AU2021201518A1/en not_active Abandoned
- 2021-08-04 JP JP2021128303A patent/JP2021184729A/ja active Pending

Also Published As

Publication number	Publication date
AU2017312361B2 (en)	2020-12-10
EP3500593A1 (en)	2019-06-26
DE102016115246B3 (de)	2017-12-14
WO2018033291A1 (en)	2018-02-22
MA45976A (fr)	2021-05-19
JP6964351B2 (ja)	2021-11-10
US10550182B2 (en)	2020-02-04
US20180319884A1 (en)	2018-11-08
TW201806973A (zh)	2018-03-01
RS62498B1 (sr)	2021-11-30
CR20190095A (es)	2019-06-13
JP2021184729A (ja)	2021-12-09
AU2017312361A1 (en)	2019-02-28
MA45976B1 (fr)	2021-09-30
TWI775768B (zh)	2022-09-01
LT3500593T (lt)	2021-11-25
US20180051080A1 (en)	2018-02-22
BR112019001922A2 (pt)	2019-07-09
EP3500593B1 (en)	2021-08-25
DE102016115246C5 (de)	2018-12-20
CN109563149A (zh)	2019-04-02
US10526407B2 (en)	2020-01-07
MX2019001769A (es)	2019-07-08
SG11201900955VA (en)	2019-03-28
PE20190477A1 (es)	2019-04-04
MX395287B (es)	2025-03-25
AU2021201518A1 (en)	2021-04-01
CA3031995A1 (en)	2018-02-22
JP2019528061A (ja)	2019-10-10

Publication	Publication Date	Title
DK3500593T3 (da)	2021-11-01	Ukendte t-cellereceptorer og immunterapi under anvendelse deraf
DK3551221T3 (da)	2022-01-24	Hidtil ukendte t-cellereceptorer og immunterapi med anvendelse deraf
DK3126381T4 (da)	2022-04-04	Claudin-6-specifikke immunoreceptorer og t-celleepitoper
DK3516160T3 (da)	2024-04-15	Brøndanordning og tilhørende fremgangsmåder
EP3562543A4 (en)	2020-11-11	STIMULATION DEVICE
DK3600409T3 (da)	2024-09-09	T-cellereceptorer og immunterapi ved hjælp deraf mod prame-positive cancere
DK3264955T3 (da)	2020-08-31	Blandeanordning og fremgangsmåde
EP3472208C0 (en)	2023-06-07	T cell receptors and uses thereof
DK3440105T3 (da)	2022-06-13	T-cellereceptorer
DK3440106T3 (da)	2021-10-04	T-cellereceptorer
DK3494133T3 (da)	2022-09-19	Anti-kras-g12d-t-cellereceptorer
DK3283106T3 (da)	2022-01-10	Terapeutiske antistoffer og anvendelser deraf
DK3405158T3 (da)	2020-03-23	Forbedret stimuleringsindretning
DK3169703T3 (da)	2020-11-16	Kimær antigenreceptor og anvendelse deraf
DK3436022T3 (da)	2022-06-20	Oxysteroler og fremgangsmåder til anvendelse heraf
DK3319612T3 (da)	2021-08-23	Oxysteroler og fremgansmåder til anvendelse derfor
DK3117777T3 (da)	2020-07-20	Spredningstomografifremgangsmåde og spredningstomografianordning
DK3233903T3 (da)	2021-02-22	Kimære antigenreceptorer og anvendelsesfremgangsmåder
DK3096684T3 (da)	2022-07-11	Anordning og fremgangsmåde til måling af kropsegenskaber
DK3468642T3 (da)	2022-05-02	Doseringsapparat og injektionsanordning
EP3703321A4 (en)	2020-11-18	CONFIGURATION PROCESS AND APPARATUS
DK3233105T3 (da)	2020-11-16	Hidtil ukendt kombination og anvendelse
DK3414420T3 (da)	2023-10-16	Brøndanordning og brøndsystem
DK3321279T3 (da)	2020-03-09	Exenatidmodificeringsmiddel og anvendelse deraf
DK3146320T3 (da)	2019-06-11	Detekteringsanordning og fremgangsmåde